Cargando…

Expression of EGFR isoform D is regulated by HER receptor activators in breast cancer cells

Human epidermal growth factor receptor isoform D (EGFR; isoform D) is a soluble protein from a 3 kb alternate mRNA transcript that arises from the human EGFR gene. Several studies have identified this circulating isoform of EGFR as a potential diagnostic biomarker for the detection of early stage of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Negrón-Vega, Lisandra, Cora, Elsa M., Pérez-Torres, Marianela, Tang, Shou-Ching, Maihle, Nita J., Ryu, Jung Su
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9418195/ https://www.ncbi.nlm.nih.gov/pubmed/36039113 http://dx.doi.org/10.1016/j.bbrep.2022.101326

Ejemplares similares

Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth
por: Xue, Lu, et al.
Publicado: (2018)

Anti-HER-2 therapy following severe trastuzumab-induced cardiac toxicity
por: Sadek, Ibrahim, et al.
Publicado: (2017)

Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2(+) Breast Cancer
por: Yu, Xiaolin, et al.
Publicado: (2017)

EGFR isoforms and gene regulation in human endometrial cancer cells
por: Albitar, Lina, et al.
Publicado: (2010)

Systemic toxicities of trastuzumab‐emtansine predict tumor response in HER2+ metastatic breast cancer
por: Tang, Shou‐Ching, et al.
Publicado: (2021)

Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics
por: Wilken, Jason A, et al.
Publicado: (2010)

The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients
por: Machleidt, Anna, et al.
Publicado: (2013)

Soluble Human Epidermal Growth Factor Receptor 2 (sHER2) as a Potential Risk Assessment, Screening, and Diagnostic Biomarker of Lung Adenocarcinoma
por: Cosentino-Boehm, Abby L., et al.
Publicado: (2013)

Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer
por: Lee, H J, et al.
Publicado: (2015)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
por: Yang, Lu, et al.
Publicado: (2022)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Anti-HER2 therapy in metastatic breast cancer: many choices and future directions
por: Wynn, Carrie S., et al.
Publicado: (2022)

Assessment and prognostic analysis of EGFR, HER2, and HER3 protein expression in surgically resected gastric adenocarcinomas
por: Tang, Daoqiang, et al.
Publicado: (2014)

Transient anabolic effects accompany epidermal growth factor receptor signal activation in articular cartilage in vivo
por: Shepard, John B, et al.
Publicado: (2013)

EGFR Soluble Isoforms and Their Transcripts Are Expressed in Meningiomas
por: Guillaudeau, Angélique, et al.
Publicado: (2012)

HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer Cells
por: Kong, Anthony, et al.
Publicado: (2008)

Novel agents that downregulate EGFR, HER2, and HER3 in parallel
por: Ferreira, Renan Barroso, et al.
Publicado: (2015)

Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer
por: Baker, Andrew T., et al.
Publicado: (2014)

EGFR Expression in HER2-Driven Breast Cancer Cells
por: Weinberg, Florian, et al.
Publicado: (2020)

Model-Based Analysis of HER Activation in Cells Co-Expressing EGFR, HER2 and HER3
por: Shankaran, Harish, et al.
Publicado: (2013)

Structure and dynamics of the EGFR/HER2 heterodimer
por: Bai, Xue, et al.
Publicado: (2023)

Inverse Regulation of EGFR/HER1 and HER2-4 in Normal and Malignant Human Breast Tissue
por: Flågeng, Marianne Hauglid, et al.
Publicado: (2013)

Carvacrol: An In Silico Approach of a Candidate Drug on HER2, PI3Kα, mTOR, hER-α, PR, and EGFR Receptors in the Breast Cancer
por: Herrera-Calderon, Oscar, et al.
Publicado: (2020)

Protein tyrosine phosphatase SHP-1 sensitizes EGFR/HER-2 positive breast cancer cells to trastuzumab through modulating phosphorylation of EGFR and HER-2
por: Wu, Yifen, et al.
Publicado: (2015)

Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice
por: Dupouy, Sandra, et al.
Publicado: (2014)

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
por: Kim, Hwang-Phill, et al.
Publicado: (2009)

Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers
por: Khelwatty, Said A, et al.
Publicado: (2015)

AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models
por: Mu, Zhaomei, et al.
Publicado: (2014)

Bispecific Antibody Conjugated Manganese-Based Magnetic Engineered Iron Oxide for Imaging of HER2/neu- and EGFR-Expressing Tumors
por: Wu, Shou-Cheng, et al.
Publicado: (2016)

Reciprocal Regulation of Annexin A2 and EGFR with Her-2 in Her-2 Negative and Herceptin-Resistant Breast Cancer
por: Shetty, Praveenkumar K., et al.
Publicado: (2012)

Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies
por: Bergado-Báez, Gretchen, et al.
Publicado: (2022)

High-Affinity Chimeric Antigen Receptor With Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms
por: Thokala, Radhika, et al.
Publicado: (2021)

Crosstalk between PRLR and EGFR/HER2 Signaling Pathways in Breast Cancer
por: Kavarthapu, Raghuveer, et al.
Publicado: (2021)

Association of EGFR mutations in second primary lung cancer and HER2 expression in breast cancer survivors
por: Jang, Yoon Jung, et al.
Publicado: (2021)

Genetic variant rs10251977 (G>A) in EGFR-AS1 modulates the expression of EGFR isoforms A and D
por: Dhamodharan, Shankar, et al.
Publicado: (2021)

Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer
por: Borrero-García, Luis D., et al.
Publicado: (2021)

Correction: Reciprocal Regulation of Annexin A2 and EGFR with Her-2 in Her-2 Negative and Herceptin-Resistant Breast Cancer
por: Shetty, Praveenkumar K., et al.
Publicado: (2012)

Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
por: Peckys, Diana B., et al.
Publicado: (2021)

Oncogenic fusion of BCAR4 activates EGFR signaling and is sensitive to dual inhibition of EGFR/HER2
por: Bae, Kieun, et al.
Publicado: (2022)

EGFR Transgene Stimulates Spontaneous Formation of MCF7 Breast Cancer Cells Spheroids with Partly Loss of HER3 Receptor
por: Troitskaya, Olga, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dhk2kpou0kf48hk6a1cgpmh25a